Supplemental Material

Published: 8 July 2023| Version 3 | DOI: 10.17632/jtz2cnyp4g.3
Contributors:
Kim Papp, Andrew Blauvelt, Lluis Puig, Mamitaro Ohtsuki, Stefan Beissert, Melinda Gooderham, Ahmad Amin, Jie Liu, Tianshuang Wu, Tofial Azam, Vassilis Stakias, Ramon Espaillat, Ranjeeta Sinvhal, Ahmed Soliman, Yinuo Pang, Michael Chen, Mark Lebwohl

Description

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

Files

Categories

Dermatology, Psoriasis

Licence